IXICO plc (IXI) AI Stock Analysis

• Market Cap: £11.35M
• Dividend Yield: N/A
• Average Volume (3M): 58.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: 7.27%
• EPS Growth: 39.64%
• Country: UK
• Employees: 81
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 92,668,594
• 10 Day Avg. Volume: 30,033
• 30 Day Avg. Volume: 58,729
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £13.00
• Price Target Upside: 6.12% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: 13.00p ▲(6.12% Upside)

IXICO plc's stock score is driven by strong corporate events and positive technical indicators, offset by financial challenges and poor valuation metrics. The company's strategic initiatives in neurodegenerative diseases are promising, but financial and profitability issues remain a concern.

IXICO plc Business Overview & Revenue Model

Company Description

IXICO plc (IXI) is a technology-enabled healthcare company specializing in the delivery of advanced imaging and data analytics services to the pharmaceutical and biotechnology sectors. The company focuses on supporting clinical trials and research, particularly in neurology, by providing insights derived from medical imaging and other data sources. IXICO's core services include imaging biomarker analysis, data management, and software solutions that enhance the efficiency and effectiveness of drug development processes.

How the Company Makes Money

IXICO generates revenue primarily through contracts with pharmaceutical and biotechnology companies for its imaging and data analytics services. The company's revenue model is based on a combination of fee-for-service agreements, project-based contracts, and long-term partnerships with clients involved in clinical trials. Key revenue streams include payments for image acquisition and analysis, data management services, and consulting for trial design and implementation. Additionally, IXICO may benefit from collaborations and partnerships with research institutions and other healthcare organizations, which can lead to increased project opportunities and shared resources, further enhancing its earnings potential.

IXICO plc Financial Statement Overview

Summary

IXICO plc is facing financial challenges with a significant decline in revenue and negative profit margins. The strong equity position provides some stability, but cash flow issues are concerning, indicating a need for strategic improvements.

Income Statement

The company has experienced a significant decline in revenue over the past year, with a negative revenue growth rate of 13.48% from 2023 to 2024. Both EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies. The net profit margin is also negative, reflecting ongoing struggles to achieve profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 84.57%, indicating financial stability. However, the debt-to-equity ratio is low at 0.03, suggesting limited leverage which could restrict growth opportunities. Return on Equity is negative, further highlighting profitability issues.

Cash Flow

The company has faced a substantial decline in free cash flow, dropping from -1.66 million in 2023 to -2.20 million in 2024. The operating cash flow to net income ratio is negative, indicating cash flow difficulties. Additionally, the free cash flow to net income ratio suggests challenges in converting earnings to cash.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	5.77M	6.67M	8.64M	9.19M	9.53M
Gross Profit	2.71M	3.27M	4.77M	5.53M	5.91M
EBITDA	-1.95M	-707.00K	750.00K	1.31M	674.00K
Net Income	-2.00M	-1.18M	1.03M	1.51M	952.00K
Balance Sheet
Total Assets	11.19M	12.99M	14.65M	14.26M	12.10M
Cash, Cash Equivalents and Short-Term Investments	1.79M	4.03M	5.77M	6.68M	7.95M
Total Debt	314.00K	387.00K	516.00K	597.00K	213.00K
Total Liabilities	1.72M	1.56M	2.16M	2.78M	2.98M
Stockholders Equity	9.46M	11.43M	12.49M	11.48M	9.12M
Cash Flow
Free Cash Flow	-2.20M	-1.66M	-815.00K	-1.54M	795.00K
Operating Cash Flow	-1.73M	302.00K	1.43M	614.00K	1.94M
Investing Cash Flow	-377.00K	-1.86M	-2.25M	-2.15M	-1.14M
Financing Cash Flow	-134.00K	-156.00K	-114.00K	270.00K	-112.00K

IXICO plc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Positive. The current price of 12.25 is above the 20-day moving average (MA) of 12.16, above the 50-day MA of 11.21, and above the 200-day MA of 10.70, indicating a bullish trend. The MACD of 0.32 indicates Positive momentum. The RSI at 60.24 is Neutral, neither overbought nor oversold. The STOCH value of 47.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:IXI.

IXICO plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	64 Neutral	£11.35M	―	-13.85%	―	7.27%	39.64%
Sector *	51 Neutral	$7.77B	-0.12	-39.78%	2.21%	22.68%	-1.42%
OBD	46 Neutral	£9.30M	―	-333.59%	―	45.22%	55.71%
APTA	46 Neutral	£17.70M	―	-99.43%	―	17.39%	96.02%
FAB	44 Neutral	£17.73M	―	-129.49%	―	14.12%	78.16%

IXICO plc Corporate Events

IXICO plc Secures Major Contracts in Alzheimer’s and Friedreich’s Ataxia Trials

IXICO plc has secured two significant contracts valued at approximately £1.3 million to provide neuroimaging services for clinical trials in Alzheimer’s Disease and Friedreich’s Ataxia. These contracts reflect the company’s strategic focus on expanding its global presence and reinforcing its leadership in the neurodegenerative disease space. The first contract involves managing and analyzing imaging for a Phase 1 Alzheimer’s trial over three and a half years, while the second contract supports a Phase 1b trial for Friedreich’s Ataxia over six years. These developments highlight IXICO’s innovative platform and its role as a thought leader in the field.

IXICO Expands Alzheimer’s Research Collaboration with GAP

IXICO plc has strengthened its collaboration with the Global Alzheimer’s Platform Foundation (GAP) by securing full data usage rights for the Bio-Hermes-002 study, a significant global research initiative in Alzheimer’s Disease (AD). This partnership enhances IXICO’s platform capabilities and positions it as a key player in the AD research ecosystem, allowing the company to accelerate its vascular biomarker analysis R&D program, extend its product offerings, and deepen relationships with leading biopharmaceutical companies. The agreement is expected to yield strong returns, advancing the understanding, diagnosis, and treatment of AD.

IXICO plc Expects Revenue Growth to Surpass Expectations in 2025

IXICO plc anticipates its revenues for the year ending 30 September 2025 to exceed expectations, reaching at least £6.3 million, marking a 9% increase from 2024. This growth is attributed to the successful implementation of its ‘Innovate Lead Scale’ strategy, which has expanded its market reach and product offerings. The company expects this positive momentum to continue into 2026, aiming for medium-term profitability, while holding at least £3.0 million in cash by the end of the financial year. The final results for the year will be announced in December 2025.

IXICO plc Issues Share Options and Announces Director Share Dealings

IXICO plc announced the issuance of 850,000 share options to key executives, including the Chief Technology Officer and Chief Business Officer, as part of a retention strategy linked to annual share price growth over three years. Additionally, the company’s CFO/COO, Grant Nash, conducted a share transaction involving the sale and repurchase of shares into his ISA account, maintaining his beneficial interest in the company.

IXICO Facilitates FDA Clearance of Alzheimer’s Blood-Based Diagnostic

IXICO has played a pivotal role in the validation of a new Alzheimer’s Disease diagnostic biomarker for Fujirebio Diagnostics, Inc., leading to the first FDA clearance of a blood-based in vitro diagnostic test for Alzheimer’s in the U.S. This milestone enhances IXICO’s capabilities in neuroimaging biomarker analyses and marks a significant advancement in early-stage Alzheimer’s diagnosis, potentially improving patient outcomes through earlier intervention.

IXICO plc Announces Shareholder Name Change Notification

IXICO plc has announced a notification of major holdings due to a name change of a shareholder from Amati AIM VCT plc to Maven Renovar VCT PLC, following a change in the investment manager to Maven Capital Partners UK LLP. This notification does not indicate any change in the position held by the company, serving purely as an informational update about the name change.

IXICO Reports Revenue Growth and Strategic Expansion in H1 2025

IXICO plc reported a 26% increase in revenue to £3.2 million for the first half of 2025, driven by diversified projects and strategic expansion in neurological disease areas. The company strengthened its operations with key hires, expanded its US footprint, and announced significant commercial partnerships, positioning itself for growth in neurodegenerative disease research.